Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 49.31 CNY -0.28%
Market Cap: 36.6B CNY

Profitability Summary

Hangzhou Tigermed Consulting Co Ltd's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Hangzhou Tigermed Consulting Co Ltd

Revenue
6.6B CNY
Cost of Revenue
-4.9B CNY
Gross Profit
1.7B CNY
Operating Expenses
-1.2B CNY
Operating Income
531.6m CNY
Other Expenses
80.6m CNY
Net Income
612.1m CNY

Margins Comparison
Hangzhou Tigermed Consulting Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
36.6B CNY
26%
8%
9%
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
55%
13%
8%
US
Thermo Fisher Scientific Inc
NYSE:TMO
214.6B USD
41%
18%
15%
US
Danaher Corp
NYSE:DHR
158.6B USD
60%
19%
14%
CH
Lonza Group AG
SIX:LONN
37.7B CHF
33%
15%
10%
US
Agilent Technologies Inc
NYSE:A
40.4B USD
52%
21%
19%
US
IQVIA Holdings Inc
NYSE:IQV
38.1B USD
34%
14%
8%
CN
WuXi AppTec Co Ltd
SSE:603259
269.6B CNY
45%
30%
34%
KR
Samsung Biologics Co Ltd
KRX:207940
74.1T KRW
53%
32%
26%
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
60%
28%
21%
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.6B EUR
46%
17%
9%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Hangzhou Tigermed Consulting Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
36.6B CNY
3%
2%
2%
2%
US
PerkinElmer Inc
LSE:0KHE
1.1T USD
3%
2%
3%
3%
US
Thermo Fisher Scientific Inc
NYSE:TMO
214.6B USD
13%
7%
9%
8%
US
Danaher Corp
NYSE:DHR
158.6B USD
7%
4%
7%
5%
CH
Lonza Group AG
SIX:LONN
37.7B CHF
8%
4%
7%
5%
US
Agilent Technologies Inc
NYSE:A
40.4B USD
21%
11%
15%
13%
US
IQVIA Holdings Inc
NYSE:IQV
38.1B USD
20%
5%
11%
8%
CN
WuXi AppTec Co Ltd
SSE:603259
269.6B CNY
24%
18%
20%
15%
KR
Samsung Biologics Co Ltd
KRX:207940
74.1T KRW
12%
8%
12%
9%
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
-414%
24%
50%
29%
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.6B EUR
7%
3%
7%
5%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less